Masaru Ishidahara

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY.

Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million.

Tolero Pharmaceuticals, Inc. manufactures and markets pharmaceutical products. It is a clinical-stage biopharmaceutical company with a single-minded purpose to alleviate human suffering through the development of medicines to treat cancer and other serious human diseases. The company is headquartered in Lehi, UT.

Resona Bank, Ltd. provides commercial banking services. It operates through the following segments: Personal, Corporate, and Market. The Personal segment handles financial services for individual customers including personal loans, asset management, and inherited asset consulting. The Corporate segment focuses on lending, asset management that uses trusts, real estate operations, enterprise pensions, and business growth support. The Market segment engages in funds, foreign and local exchanges, bonds, and derivatives. It also offers current and savings accounts, mortgages, debit and credit cards, pension and insurance products, online and phone banking, and investment trusts. The company was founded on May 15, 1918 and is headquartered in Osaka, Japan.

Nihon Medi-Physics Co., Ltd. is a leading manufacturer of radiopharmaceuticals, based in Japan. The Japanese company is engaged in ensuring stable supply and research and development of new products. It is also working on research and development of "theranostics," a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. Nihon Medi-Physics Co. was founded in 1973, and the CEO is Nobuhiko Tamura.

Altavant Sciences, Inc. is a clinical stage biopharmaceutical company, which provides therapies that treat respiratory diseases with an initial therapeutic focus in pulmonary arterial hypertension (PAH). The company is headquartered in Cary, NC.

Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan.

Sunovion Pharmaceuticals Europe Ltd. is a British European pharmaceutical company founded in 2013 that is dedicated to improving the lives of patients through the supply of essential medicines. The company is based in London, UK. The company commercializes and distributes a portfolio of specialty brands and hospital products in 40 countries worldwide, both directly and through strategic partnerships. The company's vision is to become a recognized partner of choice through their commercial excellence, patient focus, and presence across the globe. Sunovion Pharmaceuticals Europe aims to have a positive impact on society through their pioneering focus on their environment, social, and governance (ESG) goals.

Sumitomo Mitsui Banking Corp. engages in the provision of financial services centered on banking. It operates through the following business segments: Wholesale, Retail, International, Market Sales, and Headquarters Management. The Wholesale segment covers business for customers of large and medium-sized companies in Japan. The Retail segment handles business for domestic individuals and SME customers. The International segment comprises of business for overseas Japanese and non-Japanese companies. The Market Sales segment corresponds to financial market business. The Headquarters Management segment includes all other businesses not covered by other segments. The company was founded in April 2001 and is headquartered in Tokyo, Japan.

The Japan Research Institute Ltd. is a 'knowledge engineering' company, a company that offers information services, through the coordinated application of its three functions, that is, information systems, consulting, and think-tank. As a systems integrator, the company offers services in information technology (IT) strategy planning, implementation and outsourcing for a broad range of industries and activities. The company is also active in research of both domestic and foreign economic issues and formation of policy recommendation, as well as consulting in fields, such as corporate strategies and public administrative reform. In addition, the firm provides analyses and surveys for incubation activities in the creation of new markets and industries. Through these operations The Japan Research Institute offers a vision to its customers towards changes in the economic and social environment as well as developments in the IT area.

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Part of Sumitomo Chemical Co., Ltd., Sumitomo Pharma Animal Health Co., Ltd. is a Japanese company that manufactures and supplies pharmaceuticals, food ingredients, food additives, veterinary medicines, and diagnostics. The company is based in Osaka, Japan and was founded in 2010.

Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL.

Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries.